225 related articles for article (PubMed ID: 16048921)
21. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
Schuck EL; Dalhoff A; Stass H; Derendorf H
Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of standard proportion dilution test and Etest for Mycobacterium tuberculosis sensitivity to ofloxacin and ciprofloxacin].
Cavuşoğlu C; Ciçek-Saydam C; Burhanoğlu D; Ozkalay N; Ozkaya D; Ozçam H; Bilgiç A
Mikrobiyol Bul; 2002 Jan; 36(1):118-23. PubMed ID: 12476777
[TBL] [Abstract][Full Text] [Related]
24. Optimization of the use of ciprofloxacin.
Aubert G; Carricajo A; Fonsale N; Vautrin AC
Pathol Biol (Paris); 2009 May; 57(3):236-9. PubMed ID: 18328635
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function.
Huang V; Rybak MJ
J Antimicrob Chemother; 2006 Jan; 57(1):116-21. PubMed ID: 16311369
[TBL] [Abstract][Full Text] [Related]
26. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
27. The rapid development of fluoroquinolone resistance in M. tuberculosis.
Ginsburg AS; Woolwine SC; Hooper N; Benjamin WH; Bishai WR; Dorman SE; Sterling TR
N Engl J Med; 2003 Nov; 349(20):1977-8. PubMed ID: 14614180
[No Abstract] [Full Text] [Related]
28. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
Maus CE; Plikaytis BB; Shinnick TM
Antimicrob Agents Chemother; 2005 Aug; 49(8):3192-7. PubMed ID: 16048924
[TBL] [Abstract][Full Text] [Related]
29. Molecular snapshot of drug-resistant and drug-susceptible Mycobacterium tuberculosis strains circulating in Bulgaria.
Valcheva V; Mokrousov I; Narvskaya O; Rastogi N; Markova N
Infect Genet Evol; 2008 Sep; 8(5):657-63. PubMed ID: 18657631
[TBL] [Abstract][Full Text] [Related]
30. Rapid culture-based methods for drug-resistance detection in Mycobacterium tuberculosis.
Palomino JC; Martin A; Von Groll A; Portaels F
J Microbiol Methods; 2008 Oct; 75(2):161-6. PubMed ID: 18627779
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Lister PD
Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
[TBL] [Abstract][Full Text] [Related]
32. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
Boak LM; Li J; Rayner CR; Nation RL
Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144
[TBL] [Abstract][Full Text] [Related]
34. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
Kurabachew M; Lu SH; Krastel P; Schmitt EK; Suresh BL; Goh A; Knox JE; Ma NL; Jiricek J; Beer D; Cynamon M; Petersen F; Dartois V; Keller T; Dick T; Sambandamurthy VK
J Antimicrob Chemother; 2008 Oct; 62(4):713-9. PubMed ID: 18587134
[TBL] [Abstract][Full Text] [Related]
35. Maximizing efficacy and reducing the emergence of resistance.
Wise R
J Antimicrob Chemother; 2003 May; 51 Suppl 1():37-42. PubMed ID: 12702702
[TBL] [Abstract][Full Text] [Related]
36. Detection of multidrug resistance in Mycobacterium tuberculosis.
Sekiguchi J; Miyoshi-Akiyama T; Augustynowicz-Kopeć E; Zwolska Z; Kirikae F; Toyota E; Kobayashi I; Morita K; Kudo K; Kato S; Kuratsuji T; Mori T; Kirikae T
J Clin Microbiol; 2007 Jan; 45(1):179-92. PubMed ID: 17108078
[TBL] [Abstract][Full Text] [Related]
37. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
Maglio D; Kuti JL; Nicolau DP
Clin Ther; 2005 Jul; 27(7):1032-42. PubMed ID: 16154482
[TBL] [Abstract][Full Text] [Related]
38. Anti-TB drug resistance levels and patterns among Mycobacterium tuberculosis isolated from newly diagnosed cases of pulmonary tuberculosis in Dar es Salaam, Tanzania.
Matee M; Mfinanga S; Holm-Hansen C
APMIS; 2009 Apr; 117(4):263-7. PubMed ID: 19338514
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai.
Yang Y; Liao M; Gu WM; Bell K; Wu L; Eng NF; Zhang CG; Chen Y; Jolly AM; Dillon JA
J Antimicrob Chemother; 2006 Oct; 58(4):868-72. PubMed ID: 16880174
[TBL] [Abstract][Full Text] [Related]
40. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan.
Lai CC; Tan CK; Huang YT; Chou CH; Hung CC; Yang PC; Luh KT; Hsueh PR
Clin Infect Dis; 2008 Oct; 47(7):e57-63. PubMed ID: 18715157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
